Cell membrane-associated heparan sulfate is a receptor for prototype foamy virus in human, monkey, and rodent cells

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1158-1166

  Nasimuzzaman, Md ^a   Persons, Derek A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; HEPARIN LYASE; HEPARINASE III; SYNDECAN 1; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CD34 SELECTION; CELL SURFACE; CHO CELL; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HAPLORHINI; HUMAN; HUMAN CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RODENT; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; SPUMA VIRUS; SULFATION; TISSUE DISTRIBUTION; VIRUS ATTACHMENT; VIRUS INHIBITION;

HUMAN SPUMARETROVIRUS; RODENTIA;

EID: 84861908273     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.41     Document Type: Article

References (50)

1. Linial, M (2007). Foamy viruses. In: Fields BN, Knipe DM and Howley PM (eds). Fields Virology, 5th edn, vol. 1. Lippincott Williams & Wilkins: Philadelphia, pp. 2245- 2262.
2. Rethwilm, A (2007). Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors. Curr Gene Ther 7: 261-271.
3. Rethwilm, A (2010). Molecular biology of foamy viruses. Med Microbiol Immunol 199: 197-207.
4. Bauer, TR Jr, Allen, JM, Hai, M, Tuschong, LM, Khan, IF, Olson, EM et al. (2008). Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 14: 93-97.
5. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672. (Pubitemid 30241569)
6. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419. (Pubitemid 37296260)
7. Si, Y, Pulliam, AC, Linka, Y, Ciccone, S, Leurs, C, Yuan, J et al. (2008). Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells. Blood 112: 4458-4465.
8. Stanke, N, Stange, A, Lüftenegger, D, Zentgraf, H and Lindemann, D (2005). Ubiquitination of the prototype foamy virus envelope glycoprotein leader peptide regulates subviral particle release. J Virol 79: 15074-15083. (Pubitemid 43032289)
9. Duda, A, Lüftenegger, D, Pietschmann, T and Lindemann, D (2006). Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain. J Virol 80: 8158-8167. (Pubitemid 44182316)
10. Lehmann-Che, J, Renault, N, Giron, ML, Roingeard, P, Clave, E, Tobaly-Tapiero, J et al. (2007). Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathog 3: e74.
11. Ruoslahti, E (1988). Fibronectin and its receptors. Annu Rev Biochem 57: 375-413.
12. Mergia, A, Leung, NJ and Blackwell, J (1996). Cell tropism of the simian foamy virus type 1 (SFV-1). J Med Primatol 25: 2-7. (Pubitemid 126460224)
13. Stirnnagel, K, Lüftenegger, D, Stange, A, Swiersy, A, Müllers, E, Reh, J et al. (2010). Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology 7: 45.
14. Bishop, JR, Schuksz, M and Esko, JD (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446: 1030-1037. (Pubitemid 46676065)
15. Häcker, U, Nybakken, K and Perrimon, N (2005). Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 6: 530-541. (Pubitemid 40943044)
16. Kirkpatrick, CA and Selleck, SB (2007). Heparan sulfate proteoglycans at a glance. J Cell Sci 120(Pt 11): 1829-1832. (Pubitemid 46979773)
17. Summerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445. (Pubitemid 28116931)
18. Shieh, MT, WuDunn, D, Montgomery, RI, Esko, JD and Spear, PG (1992). Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116: 1273-1281.
19. WuDunn, D and Spear, PG (1989). Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63: 52-58.
20. Chen, Y, Maguire, T, Hileman, RE, Fromm, JR, Esko, JD, Linhardt, RJ et al. (1997). Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3: 866-871. (Pubitemid 27353446)
21. Esko, JD, Stewart, TE and Taylor, WH (1985). Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA 82: 3197-3201. (Pubitemid 15029573)
22. Esko, JD, Rostand, KS and Weinke, JL (1988). Tumor formation dependent on proteoglycan biosynthesis. Science 241: 1092-1096.
23. Lidholt, K, Weinke, JL, Kiser, CS, Lugemwa, FN, Bame, KJ, Cheifetz, S et al. (1992). A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proc Natl Acad Sci USA 89: 2267-2271.
24. Langford, JK, Stanley, MJ, Cao, D and Sanderson, RD (1998). Multiple heparan sulfate chains are required for optimal syndecan-1 function. J Biol Chem 273: 29965-29971. (Pubitemid 28510014)
25. Richardson, TP, Trinkaus-Randall, V and Nugent, MA (2001). Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci 114(Pt 9): 1613-1623. (Pubitemid 32454660)
26. Esko, JD and Lindahl, U (2001). Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173. (Pubitemid 32656238)
27. Lamari, FN and Karamanos, NK (2006). Structure of chondroitin sulfate. Adv Pharmacol 53: 33-48.
28. David, G (1993). Integral membrane heparan sulfate proteoglycans. FASEB J 7: 1023-1030.
29. Shukla, D, Liu, J, Blaiklock, P, Shworak, NW, Bai, X, Esko, JD et al. (1999). A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99: 13-22. (Pubitemid 29468626)
30. Hu, QY, Fink, E, Happer, M and Elder, JH (2011). Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein. J Virol 85: 7108-7117.
31. Opie, SR, Warrington, KH Jr, Agbandje-McKenna, M, Zolotukhin, S and Muzyczka, N (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77: 6995-7006. (Pubitemid 36666892)
32. Rapraeger, AC, Krufka, A and Olwin, BB (1991). Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252: 1705-1708. (Pubitemid 21917092)
33. Roghani, M and Moscatelli, D (1992). Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 267: 22156-22162.
34. Kaner, RJ, Baird, A, Mansukhani, A, Basilico, C, Summers, BD, Florkiewicz, RZ et al. (1990). Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type 1. Science 248: 1410-1413.
35. Qing, K, Mah, C, Hansen, J, Zhou, S, Dwarki, V and Srivastava, A (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77. (Pubitemid 29051001)
36. Mirda, DP, Navarro, D, Paz, P, Lee, PL, Pereira, L and Williams, LT (1992). The fibroblast growth factor receptor is not required for herpes simplex virus type 1 infection. J Virol 66: 448-457.
37. Shieh, MT and Spear, PG (1991). Fibroblast growth factor receptor: does it have a role in the binding of herpes simplex virus? Science 253: 208-210.
38. Epstein, MA, Achong, BG, Barr, YM, Zajac, B, Henle, G and Henle, W (1966). Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J Natl Cancer Inst 37: 547-559.
39. Schneider, U, Schwenk, H-U and Bornkamm, G (1977). Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer 19: 621-626. (Pubitemid 8094638)
40. Rasheed, S, Nelson-Rees, WA, Toth, EM, Arnstein, P and Gardner, MB (1974). Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33: 1027-1033.
41. Desmyter, J, Rawls, WE and Melnick, JL (1968). A human interferon that crosses the species line. Proc Natl Acad Sci USA 59: 69-76.
42. Jensen, FC, Girardi, AJ, Gilden, RV and Koprowski, H (1964). INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES WITH ROUS SARCOMA VIRUS. Proc Natl Acad Sci USA 52: 53-59.
43. Giard, DJ, Aaronson, SA, Todaro, GJ, Arnstein, P, Kersey, JH, Dosik, H et al. (1973). In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423.
44. Jainchill, JL, Aaronson, SA and Todaro, GJ (1969). Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 4: 549-553.
45. Pear, WS, Nolan, GP, Scott, ML and Baltimore, D (1993). Production of hightiter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396. (Pubitemid 23277674)
46. Löchelt, M, Zentgraf, H and Flügel, RM (1991). Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel 1 gene. Virology 184: 43-54.
47. Trobridge, G, Josephson, N, Vassilopoulos, G, Mac, J and Russell, DW (2002). Improved foamy virus vectors with minimal viral sequences. Mol Ther 6: 321-328. (Pubitemid 36305333)
48. Sharma, S, Murai, F, Miyanohara, A and Friedmann, T (1997). Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc Natl Acad Sci USA 94: 10803-10808. (Pubitemid 27430815)
49. Zhao, H, Pestina, TI, Nasimuzzaman, M, Mehta, P, Hargrove, PW and Persons, DA (2009). Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Blood 113: 5747-5756.
50. Linhardt, RJ (2001). Analysis of glycosaminoglycans with polysaccharide lyases. In: Current Protocols in Molecular Biology. Ausubel, FM, Brent, R, Kingston, RE, Moore, DD, Seidman, JG and Struhl, K (eds). Greene Pub. Associates, J. Wiley, order fulfillment: Brooklyn, N.Y. Media, Pa., 1994. pp. 17.13.17-17.13.32.